SABCS: Adding Camrelizumab to Neoadjuvant Chemo Beneficial in TNBC
By Elana Gotkine HealthDay Reporter
FRIDAY, Dec. 13, 2024 -- The addition of camrelizumab to neoadjuvant chemotherapy improves pathological complete response for patients with early or locally advanced triple-negative breast cancer, according to a study published online Dec. 13 in the Journal of the American Medical Association to coincide with the annual San Antonio Breast Cancer Symposium, held from Dec. 10 to 13 in San Antonio.
Li Chen, M.D., from the Fudan University Shanghai Cancer Center, and colleagues examined the efficacy and adverse events of camrelizumab plus chemotherapy versus placebo plus chemotherapy as neoadjuvant therapy in a randomized, phase 3 trial involving 441 patients with early or locally advanced triple-negative breast cancer. Patients were randomly assigned to receive camrelizumab 200 mg or placebo combined with chemotherapy every two weeks (222 and 219 patients, respectively).
The researchers found that pathological complete response was achieved in 56.8 and 44.7 percent of patients in the camrelizumab-chemotherapy and the placebo-chemotherapy groups, respectively (rate difference, 12.2 percent). Adverse events of grade 3 or higher occurred in 89.2 and 83.1 percent of patients in the camrelizumab-chemotherapy and placebo-chemotherapy groups, respectively, in the neoadjuvant phase; serious adverse events occurred in 34.7 and 22.8 percent, respectively; and fatal adverse events occurred in 0.9 percent of those in the camrelizumab-chemotherapy group.
"The benefits of camrelizumab-chemotherapy with respect to pathologic complete response were generally consistent across subgroups," the authors write.
This study was supported by Jiangsu Hengrui Pharmaceuticals, which manufactures camrelizumab.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted December 2024
Read this next
Minority Groups Less Likely to Receive Diagnostic Services After Abnormal Mammogram
WEDNESDAY, Feb. 19, 2025 -- For patients after screening mammography, onsite availability of most diagnostic services is similar across race and ethnicity groups, but minority...
AI Contributes to Early Detection of Clinically Relevant Breast Cancer
THURSDAY, Feb. 13, 2025 -- Artificial intelligence (AI) contributes to early detection of clinically relevant breast cancer, according to a study published online Feb. 3 in The...
Nivolumab Added to Chemo Improves Response in ER+, HER2− Breast Cancer
THURSDAY, Feb. 6, 2025 -- For patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.